Narasimhan says Novartis spin-offs including Alcon unlocked $100B in value
Spinning off Alcon, Sandoz and other non-core businesses unlocked nearly $100B in combined market cap, proving that focus on innovative medicines creates shareholder value.
Narasimhan says Novartis spin-offs including Sandoz unlocked $100B in value
Spinning off Alcon, Sandoz and other non-core businesses unlocked nearly $100B in combined market cap, proving that focus on innovative medicines creates shareholder value.